A review. Bristol-Myers Squibb and Merck & Co are co-developing muraglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, for the potential treatment of type 2 diabetes and other metabolic disorders. In Nov. 2004, approval was anticipated as early as mid-2005.
Muraglitazar Bristol-Myers Squibb/Merck / D. Barlocco. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 6:4(2005), pp. 427-434.
Muraglitazar Bristol-Myers Squibb/Merck
D. BarloccoPrimo
2005
Abstract
A review. Bristol-Myers Squibb and Merck & Co are co-developing muraglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, for the potential treatment of type 2 diabetes and other metabolic disorders. In Nov. 2004, approval was anticipated as early as mid-2005.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Muraglitazar.pdf
accesso aperto
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
89.41 kB
Formato
Adobe PDF
|
89.41 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
